Fortress Biotech

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Fortress Biotech (FBIO) Report Negative Q3 Earnings? What You Should Know

Fortress Biotech (FBIO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Fortress Biotech (FBIO) Enters Oversold Territory

NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Scott Henry, Managing Director, Senior Research Analyst and Head of Pharmaceuticals Research at ROTH Capital Partners, will host a webinar with the management team of Journey Medical Corporation (“Journey Medical”), a partner company of Fortress, on Wednesday, October 21, 2020, at 1:00 p.m. EDT. Speakers from Journey Medical will include Claude Maraoui, President and Chief Executive Officer, Robert Nevin, Chief Commercial Officer, and Nirav Jhaveri, Chief Financial Officer.

Fortress Biotech's Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners

Fortress Biotech has been struggling lately, but the selling pressure may be coming to an end soon.

Fortress Biotech Sees Hammer Chart Pattern: Time to Buy?

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortress Biotech, Inc. ("Fortress Biotech" or the "Company") (NASDAQ: FBIO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext....

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech, Inc. - FBIO

One of the company's subsidiaries received some bad news today.

Why Fortress Biotech Stock Is Plunging Today

- Caelum Biosciences, a company founded by Fortress, is collaborating with Alexion Pharmaceuticals on the studies

Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis

NEW YORK, Sept.  10, 2020  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in September 2020. The company will also host virtual one-on-one meetings during the conferences.

Fortress Biotech to Participate in Three September 2020 Virtual Investor Conferences

Fortress Biotech reports positive data from CUTX-101.

Fortress Reports Positive Data And Other News: The Good, Bad And Ugly Of Biopharma

Fortress Biotech (NASDAQ: FBIO) shares are trading higher on Friday after the company announced positive topline clinical efficacy results for CUTX-101 Copper Histidinate in the treatment of Menkes disease.

Why Fortress Biotech's Stock Is Trading Higher Today

Statistically Significant Improvement in the Primary Endpoint of Overall Survival in Menkes Disease Patients who Received Early Treatment with CUTX-101, Compared to an Untreated Historical Control, with a Nearly 80% Reduction in the Risk of Death (Hazard Ratio = 0.21, p

Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

NEW YORK, Aug.  28, 2020  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that it has entered into a $60 million loan agreement with funds managed by Oaktree Capital Management, L.P. (“Oaktree”), a leading global investment firm (the “Agreement”). The company expects the proceeds from the five-year loan will be used to refinance existing indebtedness. The loan will mature in August 2025.

Fortress Biotech Announces $60 Million Loan Agreement with Oaktree Capital Management

NEW YORK, Aug.  26, 2020  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company, today announced that it has priced an underwritten public offering of 666,666 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (“Series A Preferred Stock”) at a price of $18.00 per share, with expected gross proceeds to Fortress of approximately $12 million. In addition, Fortress has granted the underwriters a 45-day option to purchase up to 66,666 additional shares of its Series A Preferred Stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about August 31, 2020, subject to customary closing conditions.

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

NEW YORK, Aug.  12, 2020  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced a two-day summit hosted by Mayank Mamtani, of B. Riley FBR, Inc., that will feature multiple programs from Fortress’ diversified pipeline. The events will be held virtually on Tuesday, August 18, and Wednesday, August 19, 2020, beginning at 1:00 p.m. ET each day.

Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020

Product revenue for the first six months of 2020 increased 50% year-over-year to $21.4 million

Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

Rolling submission of New Drug Application to the FDA for CUTX-101 on track to begin in the fourth quarter of 2020 Rolling submission of New Drug Application to the FDA for CUTX-101 on track to begin in the fourth quarter of 2020

Fortress Biotech Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

Cyprium Therapeutics, a Fortress partner company, is developing CUTX-101 for Menkes disease

Fortress Biotech Announces Publication of Study on Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease in Molecular Genetics and Metabolism Reports

Avenue Therapeutics (ATXI), a Fortress partner company, also added

Fortress Biotech Added to Russell 3000® Index

NEW YORK, June  15, 2020  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical product candidates, today announced that Lindsay Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a company overview and host one-on-one investor meetings at the Raymond James Human Health Innovation Conference. The presentation will take place on Thursday, June 18, 2020, at 11:00 a.m. EDT. The conference will be held in a virtual meeting format.

Fortress Biotech to Present at the Raymond James Human Health Innovation Conference

Cyprium Therapeutics, a Fortress partner company, is developing CUTX-101 for Menkes disease and is on track to begin submitting a rolling New Drug Application to the FDA in the fourth quarter of 2020 Cyprium Therapeutics, a Fortress partner company, is developing CUTX-101 for Menkes disease and is on track to begin submitting a rolling New Drug Application to the FDA in the fourth quarter of 2020

Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism Reports

Oncogenuity, Inc., a Fortress partner company, enters into an agreement with Columbia University to develop a broad platform technology using oligonucleotides

Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers

NEW YORK, March  23, 2020  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “the Company”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical product candidates, today announced that its Board of Directors authorized the repurchase of up to $5 million of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (Nasdaq: FBIOP) (the “Preferred Stock”).  

Fortress Biotech Announces Up to $5 Million Series A Cumulative Redeemable Perpetual Preferred Stock Repurchase Program

NEW YORK, Feb.  24, 2020  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates, today announced that the underwriters of its recent public offering of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock have exercised in full their option and purchased an additional 93,750 shares at the public offering price of $20.00 per share. The exercise of the underwriters' option closed on February 20, 2020. After giving effect to the sale of the option shares, a total of 718,750 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock were offered and sold in the offering.

Fortress Biotech Announces Closing of Series A Preferred Stock Offering and Full Exercise of Over-Allotment Option

NEW YORK, Feb.  11, 2020  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced that it has priced an underwritten public offering of 625,000 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $20 per share, with expected gross proceeds to Fortress of $12.5 million. In addition, Fortress has granted the underwriters a 45-day option to purchase up to 93,750 additional shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about February 14, 2020, subject to customary closing conditions.

Fortress Biotech Announces  Pricing of Series A Preferred Stock Offering

Cyprium Therapeutics, a Fortress partner company, on track to begin submitting rolling New Drug Application for CUTX-101 to the FDA in the second half of 2020 Cyprium Therapeutics, a Fortress partner company, on track to begin submitting rolling New Drug Application for CUTX-101 to the FDA in the second half of 2020

News for Fortress Biotech Stock (FBIO)